She has been undertaking epidemiological and clinical research since 1989 with a specific interest in ethnic differences in disease risk and outcome. She has been a consultant to the Centre for Disease Control on epidemiological studies of lupus in the USA and she has a longstanding interest in improving the assessment, treatment and outcome of lupus and pregnancies in women with rheumatic diseases.
She has been the lead author on the development of BSR guidelines for the management of SLE that were published in October 2017 and was involved in the BSR audit of lupus management (2018-2019). She has contributed to the development of NHS England’s policy on the use of rituximab in SLE and the BSR guidelines for drugs in pregnancy in the rheumatic diseases published in 2016 (and the current revision).